Terms: = Breast cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Diagnosis
32 results:
1. Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.
Fang Y; Zhang Q; Chen Z; Guo C; Wu J
Aging (Albany NY); 2024 Jan; 16(1):322-347. PubMed ID: 38189813
[TBL] [Abstract] [Full Text] [Related]
2. Expression-Based diagnosis, Treatment Selection, and Drug Development for breast cancer.
Ye Q; Wang J; Ducatman B; Raese RA; Rogers JL; Wan YW; Dong C; Padden L; Pugacheva EN; Qian Y; Guo NL
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445737
[TBL] [Abstract] [Full Text] [Related]
3. vegfr2 targeted microbubble-based ultrasound molecular imaging improving the diagnostic sensitivity of microinvasive cervical cancer.
Zhong J; Su M; Jiang Y; Huang L; Chen Y; Huang Z; Zhang X
J Nanobiotechnology; 2023 Jul; 21(1):220. PubMed ID: 37438780
[TBL] [Abstract] [Full Text] [Related]
4. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
5. Recent Advances in Therapeutic Modalities Against breast cancer-Related Lymphedema: Future Epigenetic Landscape.
Chen K; Beeraka NM; Zhang X; Sinelnikov MY; Plotnikova M; Zhao C; Basavaraj V; Zhang J; Lu P
Lymphat Res Biol; 2023 Dec; 21(6):536-548. PubMed ID: 37267206
[No Abstract] [Full Text] [Related]
6. Mammary mucinous cystadenocarcinoma with long-term follow-up: molecular information and literature review.
Lei T; Shi YQ; Chen TB
Diagn Pathol; 2023 Feb; 18(1):13. PubMed ID: 36737820
[TBL] [Abstract] [Full Text] [Related]
7. Early Diagnostic Markers and Therapeutic Targets for Experimental breast cancer.
Ermakova NN; Pershina OV; Zhukova MA; Pakhomova AV; Pan ES; Sandrikina LA; Krupin VA; Rybalkina OY; Dygai AM; Skurikhin EG
Bull Exp Biol Med; 2022 Apr; 172(6):747-751. PubMed ID: 35501655
[TBL] [Abstract] [Full Text] [Related]
8. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
9. The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
Bouferraa Y; Haibe Y; Chedid A; Jabra E; Charafeddine M; Temraz S; Mukherji D; El Saghir N; Shamseddine A
BMC Cancer; 2022 Jan; 22(1):27. PubMed ID: 34980002
[TBL] [Abstract] [Full Text] [Related]
10. Orbital metastases from breast cancer: A retrospective analysis of 28 cases.
Grajales-Alvarez R; Gutierrez-Mata A
Cancer Treat Res Commun; 2020; 24():100184. PubMed ID: 32575027
[TBL] [Abstract] [Full Text] [Related]
11. A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma:
Niu Y; Ding Z; Deng X; Guo B; Kang J; Wu B; Fan Y
Front Endocrinol (Lausanne); 2020; 11():207. PubMed ID: 32390940
[TBL] [Abstract] [Full Text] [Related]
12. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract] [Full Text] [Related]
13. [Effect of TCF21 on proliferation, migration and vascular production of breast cancer cells].
Li PW; Wang HY; Xu LL
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):307-311. PubMed ID: 30955268
[No Abstract] [Full Text] [Related]
14. Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants.
Zarychta E; Rhone P; Bielawski K; Michalska M; Rość D; Ruszkowska-Ciastek B
Adv Med Sci; 2019 Sep; 64(2):216-223. PubMed ID: 30818220
[TBL] [Abstract] [Full Text] [Related]
15. Plasma levels of VEGF-A, VEGF B, and vegfr-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer.
Zajkowska M; Lubowicka E; Malinowski P; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2018 Dec; 65(4):621-628. PubMed ID: 30543720
[TBL] [Abstract] [Full Text] [Related]
16. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - vegfr-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of breast cancer.
Zajkowska M; Lubowicka E; Fiedorowicz W; Szmitkowski M; Jamiołkowski J; Ławicki S
Pathol Oncol Res; 2019 Oct; 25(4):1477-1486. PubMed ID: 30387014
[TBL] [Abstract] [Full Text] [Related]
17. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients.
Wang M; Ji S; Shao G; Zhang J; Zhao K; Wang Z; Wu A
Clin Transl Oncol; 2018 Jul; 20(7):906-911. PubMed ID: 29143228
[TBL] [Abstract] [Full Text] [Related]
18. Quantification of STAT3 and VEGF expression for molecular diagnosis of lymph node metastasis in breast cancer.
Chen Y; Liu Y; Wang Y; Li W; Wang X; Liu X; Chen Y; Ouyang C; Wang J
Medicine (Baltimore); 2017 Nov; 96(45):e8488. PubMed ID: 29137038
[TBL] [Abstract] [Full Text] [Related]
19. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract] [Full Text] [Related]
20. In situ validation of vegfr-2 and α v ß 3 integrin as targets for breast lesion characterization.
Ehling J; Misiewicz M; von Stillfried S; Möckel D; Bzyl J; Pochon S; Lederle W; Knuechel R; Lammers T; Palmowski M; Kiessling F
Angiogenesis; 2016 Apr; 19(2):245-254. PubMed ID: 26902100
[TBL] [Abstract] [Full Text] [Related]
[Next]
